Tuesday, June 02, 2026
Spherix, the leading independent market intelligence and advisory firm for the global life sciences industry, today announced new research highlighting how the race to dominate the $100 billion weight loss market is accelerating this quarter. Following the recent FDA approval of Wegovy® (semaglutide), developed by Novo Nordisk, the first oral GLP-1 for weight management, new data shows that doctors are adopting the daily tablet at a blistering pace just as major market competition approaches.
With the launch of Eli Lilly and Company’s rival oral candidate, orforglipron, the pressure is on for early market share. Financial analysts project the global weight loss market could exceed $100 billion over the next decade, making this a pivotal moment for oral treatments.
Data from Spherix Global Insights reveals that Novo Nordisk is successfully capitalizing on its first-mover advantage. The Launch Dynamix™: Wegovy Pill in Obesity tracking series indicates that the first oral GLP-1 has gained massive traction among both primary care physicians (PCPs) and endocrinologists within its very first month on the market.
“The immediate uptake of the Wegovy pill represents a fundamental shift in how both physicians and patients approach long-term weight management,” said Jim Hickey, Gastroenterology Franchise Head at Spherix Global Insights. “What we are seeing isn’t just a preference for oral alternatives; it is a clear expansion of the market. The convenience of a daily tablet is successfully bringing in patients who previously deferred treatment due to a hesitation around needles. Novo Nordisk’s early performance has set an exceptionally high bar for the competition.”
The data also suggests that the pill is not simply pulling patients away from existing weekly injections like injectable Wegovy or Zepbound® (tirzepatide), developed by Eli Lilly and Company. Instead, the oral format is expanding the overall treatment pool. The option of a daily pill is successfully drawing in a massive wave of new patients who previously avoided treatment entirely due to a hesitation around needles.
The long-term success of these oral treatments will come down to daily practicalities. Doctors and patients will likely choose between brands based on overall weight loss results, how well the stomach handles the medication, insurance coverage, and specific morning routines, such as required fasting windows before taking the pill.
For more details on Spherix’s primary market research reports and interactive dashboard offerings, visit or register here: https://clientportal.spherixglobalinsights.com.
About Spherix Global Insights
Spherix is a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, across the brand lifecycle. The company provides an unbiased and holistic view of the landscape within rapidly evolving specialty markets, including dermatology, gastroenterology, hematology, rheumatology, nephrology, neurology, oncology, and ophthalmology. Spherix clients stay ahead of the curve by leveraging the insights of the extensive Spherix Physician Community. Spherix’s market insights and advisory services empower clients to make better decisions and unlock opportunities for growth.
To learn more about Spherix Global Insights, visit spherixglobalinsights.com or connect through LinkedIn.
Source: https://www.pharmafocusamerica.com/pressreleases/spherix-data-reveals-explosive-demand-for-wegovy